Author Archives: Christy Owenby

CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™ Series E Financing Reflects Sustained Investor Confidence in CeQur’s Commercial Trajectory, Clinical Results, and Growing Demand for a Simpler Approach to Mealtime Insulin CeQur, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced […]

Extended 7-Day Wear and 1-Unit Dosing Clearances, and Two ADA Posters Signal a New Standard for Mealtime Insulin Management CeQur®, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced two recent FDA clearances for CeQur Simplicity™: extended wear of up to seven days and a new 1-unit (1U) device. […]

CeQur announces that its wearable insulin patch, CeQur Simplicity™, has replaced 10 million mealtime insulin injections. The company continues its momentum with expanded clinical access and key leadership appointments. CeQur®, maker of the wearable insulin patch CeQur Simplicity™, today announced a major milestone in its mission to simplify mealtime insulin delivery. Since launch, CeQur Simplicity has […]

The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its 4-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes. CeQur®, a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today […]

The CeQur Simplicity patch is now FDA-cleared for up to 4 days of wear. Each patch replaces up to 12 injections further simplifying mealtime insulin management. We’re excited to announce the FDA’s recent 510(k) clearance of CeQur Simplicity for an extended wear duration from 3 to 4 days. This update marks an advancement in mealtime insulin management […]

CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing. The company will use the […]

CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and […]

CeQur® announced the appointment of Peter B. Luther to its board of directors, effective immediately. Luther is a 29-year veteran of the medical device and diagnostics, OTC drugs and consumer-packaged goods industries.   Click here to download the press release.